| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $230,423 ) |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI169276 | Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs | 000 | 2 | NIH | 10/25/2023 | $230,423 |
| | 2024 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI141794 | Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis | 000 | 4 | NIH | 11/6/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $11,655,839 ) |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL166850 | Novel cardiopulmonary exercise testing variables to differentiate neuromuscular deconditioning from disease | 000 | 1 | NIH | 8/30/2023 | $757,446 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI146078 | Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability | 000 | 5 | NIH | 5/16/2023 | $328,099 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD109286 | Tryptophan metabolism and its role in fibroid pathogenesis | 001 | 2 | NIH | 7/14/2023 | $385,250 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HL165411 | Type I interferon regulates angiogenesis in Down Syndrome Supplement | 000 | 2 | NIH | 7/29/2023 | $201,875 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI141202 | Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | 000 | 5 | NIH | 12/2/2022 | $1,151,780 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HL165411 | Type I interferon regulates angiogenesis in Down Syndrome Supplement | 001 | 2 | NIH | 8/10/2023 | $63,274 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI141202 | Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | 001 | 5 | NIH | 2/2/2023 | $83,143 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI169276 | Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs | 000 | 1 | NIH | 11/18/2022 | $201,875 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21MH126359 | Behavioral and brain network effects of dysfunction in the cognitive cerebellum | 000 | 2 | NIH | 6/23/2023 | $222,029 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI139244 | The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections | 000 | 5 | NIH | 12/30/2022 | $450,790 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DE031382 | Oral commensal fungi and structural immunity | 000 | 2 | NIH | 5/15/2023 | $513,239 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01NS121150 | BRAIN (Biomimetic Regenerative Angiogenic Immunomodulating Nanocomposite) materials for brain repair after stroke | 000 | 2 | NIH | 12/20/2022 | $414,790 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01NS121150 | BRAIN (Biomimetic Regenerative Angiogenic Immunomodulating Nanocomposite) materials for brain repair after stroke | 001 | 2 | NIH | 1/30/2023 | $46,087 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI159221 | Unraveling transcriptomic and functional changes to immune sensing neuronal ganglia in response to allergy and bacteria | 000 | 2 | NIH | 4/6/2023 | $195,630 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI162802 | Transcriptional networks governing A. fumigatus virulence | 000 | 3 | NIH | 7/26/2023 | $657,546 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD099813 | Maternal Obesity Programs Offspring Hypothalamic Neurogenesis and Appetite: Mechanisms and Prevention of Hyperphagia-mediated Childhood Obesity | 000 | 4 | NIH | 5/12/2023 | $515,752 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI063503 | Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment | 000 | 17 | NIH | 6/14/2023 | $554,760 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD100529 | Mechanism of Long Non-coding RNAs Action in leiomyoma | 000 | 4 | NIH | 7/19/2023 | $402,687 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD099924 | Epitranscriptomic regulation of spermatogenesis and male fertility | 000 | 4 | NIH | 4/13/2023 | $376,036 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL151769 | E-Cigarette Vaping during Pregnancy and Lactation, Germ Cell Epigenetic Memory, and Transgenerational Asthma | 000 | 4 | NIH | 6/5/2023 | $456,537 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL146666 | Coronary Artery Calcium, Aortic Calcification and Density in MESA | 000 | 4 | NIH | 3/28/2023 | $742,865 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL151452 | Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants. | 000 | 4 | NIH | 3/10/2023 | $377,856 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DK132875 | Plant-Focused Nutrition in Patients with Diabetes and Chronic Kidney Disease (PLAFOND Study): A Pilot/Feasibility Study | 000 | 1 | NIH | 7/10/2023 | $292,764 |
| | 2023 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U19AI172713 | Systems Epigenomics of Persistent Bloodstream Infection | 000 | 1 | NIH | 8/10/2023 | $2,304,639 |
| | 2023 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD109286 | Tryptophan metabolism and its role in fibroid pathogenesis | 000 | 1 | NIH | 11/3/2022 | $0 |
| | 2023 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R61NS119708 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia | 000 | 1 | NIH | 5/1/2023 | $0 |
| | 2023 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U01AI116400 | Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | 000 | 5 | NIH | 8/22/2023 | $0 |
| | 2023 | 2021 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R00DE026856 | Novel Candida albicans host receptors during infection and immune response | 000 | 5 | NIH | 4/24/2023 | $0 |
| | 2023 | 2021 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | F32HD097932 | Examining the Androgenic and Progestational Effects of Novel Androgens for Male Contraception | 000 | 2 | NIH | 5/15/2023 | -$20,748 |
| | 2023 | 2020 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U01AI124319 | Systems Immunolobiology of Antibiotic-Persistent MRSA Infection | 000 | 5 | NIH | 5/15/2023 | -$20,162 |
| | 2023 | 2020 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HD097480 | Development of Immunotherapeutic Strategies to Overcome Neonatal Candidiasis | 000 | 2 | NIH | 12/1/2022 | $0 |
| | 2023 | 2020 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI124566 | Endothelial invasion by yeast-phase Candida | 000 | 5 | NIH | 7/26/2023 | $0 |
| | 2023 | 2019 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | K23DK103972 | Trajectories of Adherence to Cardiovascular Medications in Patients on Dialysis | 000 | 5 | NIH | 3/30/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $13,480,054 ) (Continued on the next page) |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | K24HL138632 | Mentorship in the Endocrinology of Sleep | 000 | 5 | NIH | 4/27/2022 | $119,586 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI130056 | Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitis | 000 | 5 | NIH | 10/18/2021 | $334,899 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI063503 | Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment | 001 | 16 | NIH | 7/15/2022 | $554,760 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21MH126359 | Behavioral and brain network effects of dysfunction in the cognitive cerebellum | 000 | 1 | NIH | 6/22/2022 | $231,150 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R61NS119708 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia | 002 | 1 | NIH | 6/2/2022 | $0 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R61NS119708 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia | 001 | 1 | NIH | 5/3/2022 | $86,659 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R61NS119708 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia | 000 | 1 | NIH | 4/16/2022 | $422,068 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI141202 | Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | 000 | 4 | NIH | 12/7/2021 | $1,047,323 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U01AI116400 | Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | 000 | 5 | NIH | 6/28/2022 | $1,002,378 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 WEST CARSON ST. | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI146078 | Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability | 000 | 4 | NIH | 5/23/2022 | $328,099 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD100529 | Mechanism of Long Non-coding RNAs Action in leiomyoma | 000 | 3 | NIH | 7/8/2022 | $402,687 |
| | 2022 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD099813 | Maternal Obesity Programs Offspring Hypothalamic Neurogenesis and Appetite: Mechanisms and Prevention of Hyperphagia-mediated Childhood Obesity | 000 | 3 | NIH | 6/25/2022 | $517,655 |
|
